Heterozygous Familial Hypercholesterolemia (HeFH) Treatments

CRESTOR is indicated: To reduce the risk of major adverse cardiovascular events in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein ≥2 mg/L, and at least one additional CV risk factor., As an adjunct to diet to: ∘ Reduce low-density lipoprotein cholesterol in adults with primary hyperlipidemia. ∘ Reduce LDL-C and slow the progression of atherosclerosis in adults. ∘ Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia ., As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia ., As an adjunct to diet for the treatment of adults with: ∘ Primary dysbetalipoproteinemia. ∘ Hypertriglyceridemia. CRESTOR is an HMG Co‑A reductase inhibitor indicated: , To reduce the risk of major adverse cardiovascular events in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein ≥2 mg/L, and at least one additional CV risk factor., As an adjunct to diet to: ∘ reduce LDL-C in adults with primary hyperlipidemia. ∘ reduce LDL-C and slow the progression of atherosclerosis in adults. ∘ reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia ., As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia ., As an adjunct to diet for the treatment of adults with: ∘ Primary dysbetalipoproteinemia. ∘ Hypertriglyceridemia.